| 2024-04-29 19:00 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-04-29 18:35 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-02-20 19:26 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-02-20 19:26 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-02-15 12:04 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2024-02-15 12:04 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | SEDAR MD & A815 | SEDAR MD & A |
| 2024-01-08 12:06 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | News Release200 | Lobe Sciences reviews 2023 activities |
| 2023-12-07 10:09 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | News Release200 | Lobe Sciences talks results of phase 1 L-130 trial |
| 2023-12-05 09:56 | CC:LOBE | Lobe Sciences Ltd (2) | 0.025 | News Release200 | Lobe's psilocin compound shelf stable 12 months |
| 2023-09-18 13:55 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | News Release200 | Lobe Sciences appoints Lee as CFO |
| 2023-09-14 18:13 | CC:LOBE | Lobe Sciences Ltd (2) | 0.02 | News Release200 | Lobe amends share purchase deal with Altemia |
| 2023-08-01 13:42 | CC:LOBE | Lobe Sciences Ltd (2) | 0.025 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-07-01 02:36 | CC:LOBE | Lobe Sciences Ltd (2) | 0.03 | News Release200 | Lobe Sciences clarifies Altemia acquisition disclosure |
| 2023-06-27 10:47 | CC:LOBE | Lobe Sciences Ltd (2) | 0.025 | News Release200 | Lobe Sciences begins phase 1 clinical trial of L-130 |
| 2023-06-07 11:38 | CC:LOBE | Lobe Sciences Ltd (2) | | News Release200 | Lobe Sciences appoints Phillips as COO |
| 2023-05-17 13:02 | CC:LOBE | Lobe Sciences Ltd (2) | 0.035 | News Release200 | Lobe Sciences, Pentec to roll out Altemia in U.S. |